

INFORMATION DISCLOSURE
CITATION

ATTY. DOCKET NO.

SERIAL NO.

622-39

09/524,747

APPLICANT

REINER et al


FILING DATE

GROUP

March 15, 2000

1623

(Use several sheets if necessary)



U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
						NOV 06 2003
						TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
6 0 466 650 A2	01/1992	EP			

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

8/0	1	Henry, D., et al; "Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis"; BMJ; Vol. 312, pp. 1563-1566, (1996).
8/0	2	Walker, A.M.; "Quantitative studies of the risk of serious hepatic injury in persons using nonsteroidal antiinflammatory drugs"; Arthritis and Rheumatism, Vol. 40, No. 2, pp. 201-208 (1997).
8/0	3	Gutthann, S.P., et al; "Nonsteroidal anti-inflammatory drugs and the risk of hospitalization for acute renal failure"; Arch. Intern. Med., Vol. 156, pp. 2433-2439, (1996)
8/0	4	Amidon, G.L., et al; "A theoretical basis for a biopharmaceutic drug classification: The correlation of <i>in vitro</i> drug product dissolution and <i>in vivo</i> bioavailability"; Pharm. Research, Vol. 12, No. 3, pp. 413-420, (1995).
8/0	7	Neuvonen, P.J., "The effect of magnesium hydroxide on the oral absorption of ibuprofen, ketoprofen and diclofenac"; Br. J. Clin. Pharmac. Vol. 31, pp. 263-266, (1991).
8/0	8	Neuvonen, P.J., et al; "Enhancement of drug absorption by antacids"; Clin. Pharmacokinet. 27 (2): pp. 120-128, (1994).
8/0	9	Neuvonen, P.J., et al; "Effect of magnesium hydroxide on the absorption of tolfenamic and mefenamic acids"; Eur. J. Clin. Pharmacol, 35: pp. 495-501, (1988).
8/0	10	Derendorf, H., et al; "Pharmacokinetics of diclofenac sodium after intramuscular administration in combination with triamcinolone acetate"; Eur. J. Clin. Pharmacol., 31:363-365 (1986).
8/0	11	Terhaag, B., et al; "Bioavailability of a new effervescent tablet of diclofenac"; Int. J. Clin. Pharmacol. Ther., 38:546:551 (2000).
8/0	12	Lotsch, J., et al.; "Population pharmacokinetics of fast release oral diclofenac in healthy volunteers: relation to pharmacodynamics in an experimental pain model"; Pharmaceutical Research, Vol. 17, No. 1, pp. 77-84, (2000).
8/0	13	Marzo, A., et al; "Pharmacokinetics of Diclofenac after oral administration of its potassium salt in sachet and tableted formulations"; Arzneimittel. Forsch., 50:43-47 (2000).
8/0	14	Reiner, V., et al; "Increased absorption rate of diclofenac from fast acting formulations containing its potassium salt"; Arzneimittel. Forsch., 51:885-890 (2001).
8/0	15	Fourtillan, J.B., et al; "Etude pharmacocinetique du piroxicam chez l'homme sain", Therapie, Vol. 38, pp. 163-170, (1983).
8/0	16	Brogden, R.N., et al; "Diclofenac sodium: A review of its pharmacological properties and therapeutic use in rheumatic diseases and pain of varying origin"; Drugs, 20: pp. 24-48, (1980).
8/0	17	Macia, M.A., et al; "Comparative bioavailability of a dispersible formulation of diclofenac and finding of double plasma peaks"; Int. J. Clin Pharmacol. Ther., 33:333-339 (1995).

*Examiner

Date Considered

2/9/04

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

INFORMATION DISCLOSURE
CITATION

ATTY. DOCKET NO.

SERIAL NO.

622-39

09/524,747

APPLICANT

REINER et al


FILING DATE

GROUP

March 15, 2000

1623

(Use several sheets if necessary)



Ho	18	Bedini, R., et al; "Swelling force development as a result of hydrate formation in diclofenac sodium or nitrofurantoin tablets"; S.T.P. Pharma Sciences 10 (4) pp. 335-339, (2000).
Ho	19	Henrikson, P.A., et al; "Absorption and effect of diclofenac sodium after surgical removal of a lower wisdom tooth; Curr. Ther. Res., 31:30-26 (1982).
Ho	20	Degen, P.H., et al; "Pharmacokinetics of diclofenac and five metabolites after single doses in healthy volunteers and after repeated doses in patients"; Xenobiotica, 18:1449-1455 (1988).
Ho	21	Maggi, C.A., et al; "Comparative bioavailability of diclofenac hydroxyethylpyrrolidine vs diclofenac sodium in man"; Eur. J. Clin. Pharmacol., 38:207-208 (1990).
Ho	22	Mendes, G.B.B., et al; "Comparative bioavailability of two suspension formulations of potassium diclofenac in healthy male volunteers"; Int. J. Clin. Pharmacol. Ther., 32:131-135 (1994).
Ho	23	Crook, P.R., et al; "The pharmacokinetics of diclofenac sodium in patients with active rheumatoid disease"; Eur. J. Clin. Pharmacol., 21:331-334 (1982).
Ho	24	Willis, J.V., et al; "The pharmacokinetics of diclofenac sodium following intravenous and oral administration"; Eur. J. Clin. Pharmacol., 16:405-410 (1979).
Ho	25	Willis, J.V., et al; "The influence of food on the absorption of diclofenac after single and multiple oral doses"; Eur. J. Clin. Pharmacol., 19:33-37 (1981).
Ho	26	Riess, W., et al; "Pharmacokinetics and metabolism of the anti-inflammatory agent Volten" Scand. J. Rheumatol., Suppl. 22:17-29 (1978).
Ho	27	Physicians' Desk Reference; Novartis Pharmaceutical Corp., pp. 1830-1832 (2000).

RECEIVED

NOV 06 2003

TECH CENTER 1600/2900

*Examiner

Date Considered

2/19/04

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.